title: Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
abstract: As a result of recent progress in detection techniques, circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) can now be accurately detected in the blood of most cancer patients. While these new biomarkers can provide a better understanding of key biological mechanisms underlying cancer growth and dissemination, they also open up a wide range of possible clinical applications in medical oncology, radiation oncology and surgical oncology. In this review, we summarize the results obtained with ctDNA and CTC together with their potential future clinical applications in the field of surgical oncology, with particular focus on the perioperative setting of various types of cancer. These applications include, but are not limited to, cancer screening, early diagnosis, prognostic assessment, evaluation and management of preoperative systemic or local therapies, post-surgical detection of minimal residual disease and early detection of cancer relapse.
authors.affiliation: Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Cabel
authors.affiliation: Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Proudhon
authors.affiliation: Institut Curie, PSL Research University, Department of Surgical Oncology, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Mariani
authors.affiliation: Institut Curie, PSL Research University, Department of Surgical Oncology, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Tzanis
authors.affiliation: Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Beinse
authors.affiliation: Institut Curie, PSL Research University, Department of Genetics, Paris, France; Université Paris Descartes, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Bieche
authors.affiliation: Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France; Université Paris Descartes, Paris, France.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Pierga
authors.affiliation: Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France; Université Paris-Saclay, Saint Cloud, France.
authors.forename: F-C
authors.initials: FC
authors.lastname: Bidard
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy / Q000379:methods; D004273:DNA, Neoplasm / Q000097:blood*; D055088:Early Detection of Cancer; D006801:Humans; D018365:Neoplasm, Residual; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D009360:Neoplastic Cells, Circulating; D011184:Postoperative Period; D057234:Preoperative Period; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm
keywords: Circulating tumor DNA; Circulating tumor cells; Minimal residual disease; Neoadjuvant; Surgery